Deutsche Märkte geschlossen

Addex Therapeutics Ltd (ADXN.SW)

Swiss - Swiss Verzögerter Preis. Währung in CHF
Zur Watchlist hinzufügen
0,0580-0,0058 (-9,09%)
Börsenschluss: 05:31PM CEST

Addex Therapeutics Ltd

Chemin des Mines, 9
Geneva 1202
Switzerland
41 22 884 1555
https://www.addextherapeutics.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter23

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Timothy Mark DyerCo-Founder, CEO & DirectorN/AN/A1968
Dr. Roger G. Mills M.D.Chief Medical Officer & DirectorN/AN/A1957
Mr. Lénaic TeyssédouHead of FinanceN/AN/A1986
Dr. Mikhail Kalinichev Ph.D.Head of Translational ScienceN/AN/A1967
Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CHF.

Beschreibung

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Corporate Governance

Addex Therapeutics Ltds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.